Ali A El-Solh1, Mifue Okada, Celestino Pietrantoni, Alan Aquilina, Eileen Berbary. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, School of Medicine and Biomedical Sciences, Erie County Medical Center, University at Buffalo, Buffalo, NY 14215 , USA. solh@buffalo.edu
Abstract
OBJECTIVE: To determine the homeostatic balance of patients with ventilator-associated pneumonia (VAP) with respect to the adequacy of antimicrobial therapy. DESIGN AND SETTING: Descriptive observational study in a 12-bed medical intensive care unit in a university-affiliated hospital. PATIENTS: Twenty-nine patients with VAP documented by quantitative culture of bronchoalveolar secretions and a control group of eight mechanically ventilated patients. METHODS: Serial bronchoalveolar lavage fluid (BALF) samples were assayed for prothrombin activation fragment (F1+2), thrombin-antithrombin (TAT) complex, fibrinolytic activity, urokinase-type plasminogen activator (u-PA), and plasminogen activator inhibitor type 1 (PAI-1) on days 1, 4, and 7 after VAP onset. RESULTS: Pathogens isolated from patients with inadequate empirical antimicrobial coverage included methicillin-resistant Staphylococcus aureus (n=2), Pseudomonas aeruginosa (n=4), and Acinetobacter baumannii (n=1). Compared to those who received adequate antibiotic therapy, TAT, F1+2, and PAI-1 levels increased while u-PA levels remained unchanged. Despite antibiotic adjustment on day 4, TAT levels remained elevated in those who lacked adequate antimicrobial coverage and were significantly correlated with PaO(2)/FIO(2). The procoagulant activity was accompanied by a local depression of fibrinolytic capacity that was attributed mainly to increased BALF PAI-1 levels. Nonsurvivors showed significantly higher levels of TAT and PAI-1 than survivors. No significant correlation between the bacterial burden and the homeostatic derangements was documented. CONCLUSIONS: The lung inflammatory response seems to promulgate a local procoagulant activity associated with hypoxemia in those with inadequate antibiotic therapy. The homeostatic derangement seems to be independent of the lung bacterial burden.
OBJECTIVE: To determine the homeostatic balance of patients with ventilator-associated pneumonia (VAP) with respect to the adequacy of antimicrobial therapy. DESIGN AND SETTING: Descriptive observational study in a 12-bed medical intensive care unit in a university-affiliated hospital. PATIENTS: Twenty-nine patients with VAP documented by quantitative culture of bronchoalveolar secretions and a control group of eight mechanically ventilated patients. METHODS: Serial bronchoalveolar lavage fluid (BALF) samples were assayed for prothrombin activation fragment (F1+2), thrombin-antithrombin (TAT) complex, fibrinolytic activity, urokinase-type plasminogen activator (u-PA), and plasminogen activator inhibitor type 1 (PAI-1) on days 1, 4, and 7 after VAP onset. RESULTS: Pathogens isolated from patients with inadequate empirical antimicrobial coverage included methicillin-resistant Staphylococcus aureus (n=2), Pseudomonas aeruginosa (n=4), and Acinetobacter baumannii (n=1). Compared to those who received adequate antibiotic therapy, TAT, F1+2, and PAI-1 levels increased while u-PA levels remained unchanged. Despite antibiotic adjustment on day 4, TAT levels remained elevated in those who lacked adequate antimicrobial coverage and were significantly correlated with PaO(2)/FIO(2). The procoagulant activity was accompanied by a local depression of fibrinolytic capacity that was attributed mainly to increased BALF PAI-1 levels. Nonsurvivors showed significantly higher levels of TAT and PAI-1 than survivors. No significant correlation between the bacterial burden and the homeostatic derangements was documented. CONCLUSIONS: The lung inflammatory response seems to promulgate a local procoagulant activity associated with hypoxemia in those with inadequate antibiotic therapy. The homeostatic derangement seems to be independent of the lung bacterial burden.
Authors: Anita W Rijneveld; Marcel Levi; Sandrine Florquin; Peter Speelman; Peter Carmeliet; Tom van Der Poll Journal: J Immunol Date: 2002-04-01 Impact factor: 5.422
Authors: S Idell; K Gonzalez; H Bradford; C K MacArthur; A M Fein; R J Maunder; J G Garcia; D E Griffith; J Weiland; T R Martin Journal: Am Rev Respir Dis Date: 1987-12
Authors: P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk Journal: Anal Biochem Date: 1985-10 Impact factor: 3.365
Authors: M Levi; T van Der POLL; H ten CATE; B Kuipers; B J Biemond; H M Jansen; J W ten CATE Journal: Am J Respir Crit Care Med Date: 1998-07 Impact factor: 21.405
Authors: B J Biemond; M Levi; H ten Cate; H R Soule; L D Morris; D L Foster; C A Bogowitz; T van der Poll; H R Büller; J W ten Cate Journal: Thromb Haemost Date: 1995-02 Impact factor: 5.249
Authors: Ali A El Solh; Milapchand Bhora; Lilibeth Pineda; Alan Aquilina; Laurie Abbetessa; Eileen Berbary Journal: Intensive Care Med Date: 2005-11-12 Impact factor: 17.440
Authors: Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin Journal: Int J Mol Sci Date: 2021-06-14 Impact factor: 5.923
Authors: Esther K Wolthuis; Alexander P J Vlaar; Jorrit-Jan H Hofstra; Joris J T H Roelofs; Vivian de Waard; Nicole P Juffermans; Marcus J Schultz Journal: Crit Care Res Pract Date: 2011-07-14
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-12-18 Impact factor: 17.440
Authors: J Bartko; C Schoergenhofer; M Schwameis; N Buchtele; J Wojta; G Schabbauer; L Stiebellehner; B Jilma Journal: J Thromb Haemost Date: 2016-10-24 Impact factor: 5.824